@article{4e62e5c6af0a43c8b47f48e9b6707611,
title = "First-Line Therapy for Chronic Lymphocytic Leukemia: Bruton Tyrosine Kinase or BCL2 or Both?",
keywords = "BCL2 inhibitor, BTK inhibitor, Chronic lymphocytic leukemia, Combination therapy, Novel therapy",
author = "Cherng, {Hua Jay J.} and Nitin Jain",
note = "Funding Information: H-J.J. Cherng has no disclosures to declare. N. Jain has received research funding from Pharmacyclics, AbbVie , Genentech , AstraZeneca , BMS , Pfizer , ADC Therapeutics , Incyte , Servier , Cellectis , Adaptive Biotechnologies , Precision Biosciences , Aprea Therapeutics , and Fate Therapeutics and has received honoraria from Pharmacyclics, Janssen, AbbVie, Genentech, AstraZeneca, Adaptive Biotechnologies, Cellectis, Servier, Precision Biosciences, Beigene, TG Therapeutics, and ADC Therapeutics.",
year = "2021",
month = aug,
doi = "10.1016/j.hoc.2021.03.005",
language = "English (US)",
volume = "35",
pages = "725--738",
journal = "Hematology/Oncology Clinics of North America",
issn = "0889-8588",
publisher = "W.B. Saunders Ltd",
number = "4",
}